Pfizer and UCL to develop stem-cell therapies for macular degeneration
This article was originally published in Scrip
Executive Summary
Pfizer is to provide funding to University College London (UCL) to develop new stem-cell treatments for age-related macular degeneration (AMD) and other retinal diseases.